Telesis Bio, Inc. (TBIO)
| Market Cap | 19.82K +999.9% |
| Revenue (ttm) | 17.03M -32.5% |
| Net Income | -47.93M |
| EPS | -28.02 |
| Shares Out | 1.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 696 |
| Open | 0.0110 |
| Previous Close | n/a |
| Day's Range | 0.0110 - 0.0110 |
| 52-Week Range | 0.0001 - 0.1500 |
| Beta | 2.47 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About Telesis Bio
Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an in... [Read more]
Financial Performance
In 2023, Telesis Bio's revenue was $27.51 million, an increase of 0.27% compared to the previous year's $27.44 million. Losses were -$49.02 million, 1.14% more than in 2022.
Financial StatementsNews
Telesis Bio Slides: Investor presentation
Telesis Bio has posted slides in relation to its latest quarterly earnings report, which was published on January 12, 2026.
Telesis Bio, Regeneron partner for rapid DNA, gene synthesis
Telesis Bio (TBIO) announced a new license agreement with Regeneron Pharmaceuticals (REGN) to deploy Telesis Bio’s Gibson SOLA platform at its R&D core facilities. The company stated this will help…
Telesis Bio Quarterly report: Q3 2024
Telesis Bio has published its Q3 2024 quarterly earnings report on November 7, 2024.
Telesis Bio and Beckman Coulter team to enable ‘breakthrough’ discoveries
A new partnership between Telesis Bio (TBIO)and Beckman Coulter Life Sciences (BEC) will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesi...
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Trevena (TRVN), 1,645% surge in interest Telesis Bio (TBI...
Telesis Bio to delist shares from Nasdaq
Telesis Bio announced that it has notified the Nasdaq Stock Market of its decision to delist the Company’s shares of common stock, par value $0.001 per share and deregister the…
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO) (“Telesis” or the “Company”), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic d...
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, fle...
Telesis Bio Quarterly report: Q2 2024
Telesis Bio has published its Q2 2024 quarterly earnings report on August 7, 2024.
Telesis Bio Earnings release: Q2 2024
Telesis Bio released its Q2 2024 earnings on August 7, 2024, summarizing the period's financial results.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Exicure (XCUR), 538% surge in interest Telesis Bio (TBIO)...
Telesis Bio Reports First Quarter 2024 Financial Results
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flex...
Telesis Bio Quarterly report: Q1 2024
Telesis Bio has published its Q1 2024 quarterly earnings report on May 9, 2024.
Telesis Bio Earnings release: Q1 2024
Telesis Bio released its Q1 2024 earnings on May 9, 2024, summarizing the period's financial results.
Telesis Bio Announces Reverse Stock Split
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (the Company) (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through ...
Telesis Bio Proxy statement: Proxy Filing
Telesis Bio filed a proxy statement on April 19, 2024, providing details for shareholder voting and corporate governance matters.
Telesis Bio announces strategic focus on Gibson SOLA EDS platform
Telesis Bio announced a focus in strategy enabled by the commercial availability of its groundbreaking Gibson SOLA enzymatic DNA synthesis, EDS, platform. Going forward, the company will increasingly ...
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in strategy enabled by the comme...
Telesis Bio Proxy statement: Proxy Filing
Telesis Bio filed a proxy statement on April 9, 2024, providing details for shareholder voting and corporate governance matters.
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, fl...
Telesis Bio Annual report: Q4 2023
Telesis Bio has published its Q4 2023 annual report on March 28, 2024.
Telesis Bio Earnings release: Q4 2023
Telesis Bio released its Q4 2023 earnings on March 28, 2024, summarizing the period's financial results.
Telesis Bio Transcript: TD Cowen 44th Annual Health Care Conference 2024
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Telesis Bio (TBIO), 358% surge in interest Agios Pharmace...